Divigel® offers an estradiol gel in five dosing options for individualized treatment of moderate to severe vasomotor symptoms due to menopause:

Divigel® is the only estrogen therapy to offer the lowest FDA-approved transdermal estradiol gel or spray available at 0.25 mg/day.¹

0.25 mg 0.5 mg 0.75 mg 1 mg 1.25 mg

Divigel® is effective at reducing hot flashes²

Divigel® reduced the frequency of vasomotor symptoms²

Chart illustrating Divigel’s® effectiveness in 2, 4, and 12-week increments.

This was a 12-week, randomized, double-blind, placebo-controlled clinical trial of 488 post-menopausal women who received 1 mg, 0.5 mg, or 0.25 mg of Divigel® or placebo gel daily.² 98.6% [481/488] of all patients had severe vasomotor symptoms at baseline.²

*0.5 mg/day is not statistically significant from placebo until week 4 and beyond, and week 5 and beyond 0.25/day.

At the highest dose (1 mg/day) Divigel® eliminated nearly 9 out of 10 daily hot flashes by week 12.²
As early as 2 weeks, Divigel® (1 mg/day) was shown to reduce the frequency of hot flashes by nearly HALF.²
At the lowest dose (0.25 mg/day) Divigel® eliminated about 70% of daily hot flashes by 12 weeks.²
Efficacy studies were not required for approval of the 0.75 mg and 1.25 mg dose strengths; therefore, data on reduction in frequency and severity for these two strengths cannot be provided.

Divigel® reduced the severity of vasomotor symptoms in 12 weeks²

Chart illustrating the differences between 0.25 mg, 0.5 mg, 1 mg doses and a placebo.

This was a 12-week, randomized, double-blind, placebo-controlled clinical trial of 488 post-menopausal women who had severe hot flash symptoms

Data remain significant from placebo at week 12.

Divigel® reduced the severity of hot flashes by 67% at 12 Weeks (1 mg/day).²
All dose strengths have been proven to reduce the severity of hot flashes.²
0.25 mg is not statistically significant until 7 weeks.²
On Divigel® your patients may not only experience fewer hot flashes and night sweats over time but those symptoms may also be less severe.²
Efficacy studies were not required for approval of the 0.75 mg and 1.25 mg dose strengths; therefore, data on reduction in frequency and severity for these two strengths cannot be provided.

Divigel® provides 24-hour estradiol coverage³

MEAN SERUM ESTRADIOL CONCENTRATION [PG/ML]

Chart showing that Divigel® provides 24- hour estradiol coverage.

Divigel® sustained serum concentrations of estradiol over 24 hours.

MEAN SERUM ESTRADIOL CONCENTRATIONS [C_avg]^*3

1 mg/day

0.5 mg/day

0.25 mg/day

30.5 pg/mL

21 pg/mL

9.8 pg/mL*

*Day 14 following multiple daily doses of Divigel® 0.1% [values uncorrected for baseline].

Divigel® offers 5 dosing options for individualized treatment.
Only Divigel® offers the lowest dose of topical estrogen get or spray available for hot flashes (0.25mg/day estradiol)¹
Efficacy studies were not required for approval of the 0.75 mg and 1.25 mg dose strengths; therefore, data on reduction in frequency and severity for these two strengths cannot be provided.

DELIVERED THROUGH THE SKIN

Although the clinical significance has not been determined, estradiol from Divigel® does not undergo first pass metabolism.^4,5

DIVIGEL^® TOPICAL GEL

Small Divigel® estrogen hormone therapy package.

SKIN

BLOODSTREAM

ESTROGEN RECEPTORS

ORAL TREATMENTS

MOUTH

STOMACH

BLOODSTREAM

LIVER

BLOODSTREAM

ESTROGEN RECEPTORS

Image illustrating how estrogen pills must pass through the mouth, stomach, bloodstream, liver, and bloodstream before they can influence estrogen receptors.

Effective Relief

Samples

Savings Offers

Dosing & Administration

REFERENCES
1. Orange Book: Approved Drug Products with Therapeutic equivalence Evaluations. U.S. Food & Drug Administration. Accessed February 13, 2020. https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm
2. Hedrick RE, Ackerman RT, Koltun WD, Halvorsen MB, Lambrecht LJ. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. Menopause. 2009;16(1):132-140.
3. Divigel® [package insert]. Vertical Pharmaceuticals, LLC; 2019.
4. Goodman NF, Cobin RH, Ginzburg SB, Katz IA, Woode DE; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. Endocr Pract. 2011;17(suppl 6):1-25.
5. Samsioe G. Transdermal hormone therapy: gels and patches. Climacteric. 2004;7(4):347-356.